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Abstract
Background: More than 50% of patients with type 2 diabetes have hypertension in Uganda. Diabetic patients with
elevated systolic blood pressure experience higher all-cause mortality and cardiovascular events compared with
normotensive diabetic individuals, hence escalating resource utilization and cost of care. The aim of this study is to
determine the effect of a nurse-led lifestyle choice and coaching intervention on systolic blood pressure among
type 2 diabetic patients with a high atherosclerotic cardiovascular risk.
Methods: This is a cluster-randomized study comprising two arms (intervention and non-intervention—control arm)
with four clusters per arm with 388 diabetic patients with a high predicted 10-year atherosclerotic cardiovascular risk.
The study will be implemented in 8 health facilities in Uganda. The intervention arm will employ a nurse-led lifestyle
choice and coaching intervention. Within the intervention, nurses will be trained to provide structured health
education, protocol-based hypertension management, and general atherosclerotic cardiovascular risk factor
management, 24-h phone calls, and 2-monthly text messaging. The control group will be constituted by the usual
care. The primary outcome measure is the mean difference in systolic blood pressure between the intervention and
usual care groups after 6 months. The study is designed to have an 80% statistical power to detect an 8.5-mmHg mean
reduction in systolic blood pressure from baseline to 6months. The unit of analysis for the primary outcome is the
individual participants. To monitor the effect of within-cluster correlation, generalized estimating equations will be used
to assess the changes over time in systolic blood pressure as a continuous variable.
Discussion: The data generated from this trial will inform change in the policy of shifting task of screening of
hypertension and atherosclerotic cardiovascular disease from doctors to nurses.
Trial registration: Pan African Trials Registry PACTR 202001916873358. Registered on 6 October 2019
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Type 2 diabetes, Randomized controlled trial
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Introduction
Background and rationale {6a}
By 2040, it is estimated that 642 million people will have
type 2 diabetes worldwide while 1.39 billion people
already have hypertension [1].
In Sub-Saharan Africa, hypertension affects younger
age groups than in the developed world and is the major
risk factor for heart failure, stroke, and kidney failure [2]
This risk increases when one has diabetes.
In Uganda, the prevalence of hypertension is high
ranging from 11 to 32% [3–7]. In a nationwide STEPS
survey covering all major regions of the country with 3906
participants, the prevalence of hypertension was 26.4% [8].
More than 50% of patients with type 2 diabetes have
hypertension [9].
Both conditions orchestrate cardiovascular disease [1,
2, 8]. There is a bi-directional relationship between dia-
betes and hypertension as patients with hypertension
have insulin resistance and are at risk of developing dia-
betes in their lifetime [1].
The two conditions share similar pathophysiological
pathways, namely endothelial dysfunction, vascular
inflammation, arterial remodeling, atherosclerosis,
dyslipidemia, and obesity [1, 9] Further analysis of
Framingham data showed higher all-cause mortality, car-
diovascular events in hypertensive diabetic patients com-
pared with normotensive diabetics resulting from
excessive atherosclerotic cardiovascular disease(ASCVD)
risk [10].
A combination of diabetes and hypertension portends
higher costs and resource utilization as this patient cohort
suffers more myocardial infarctions and acute ischemic
events, thus escalating the cost of care [9, 11]. In the USA,
in a study by the National Health and Nutritional Survey
(NHANES) 2005–2008, only 50% of hypertensive
individuals had their blood pressure under control [12].
In Sub-Saharan Africa, the majority of patients have
poorly controlled hypertension resulting from poor ac-
cess to care and shortage of physicians [13].
In all the prevalence studies in Uganda, there are low
rates of awareness of the condition among the patients
[5, 6, 8, 14], resulting in low rates of treatment [4, 5],
and control [2] leading to hypertension-related cardio-
vascular disease.
Among diabetic individuals, early landmark trials have
demonstrated the benefits of strict BP control as it is
associated with a reduction in heart failure and myocardial
infarction (United Kingdom Prospective Diabetes Study
(UKPDS) [15], Hypertension Optimal Treatment (HOT)
[16], Systolic Hypertension in the Elderly (SHEP) [17], and
Systolic Hypertension in Europe (Syst-Eur) [18]) though
there is still controversy on the blood pressure target
among type 2 diabetic patients.
Additionally, decreasing systolic blood pressure by
10 mmHg results in a 12% reduction of diabetes-related
complications [19, 20].
Despite sufficient evidence for the benefit of
hypertension control among type 2 diabetes, there is
suboptimal control of blood pressure. In one systemic
review of observational studies on treatment and blood
pressure control in 47,964 people with diabetes and
hypertension, control of blood pressure in patients with
diabetes was suboptimal with less than 12% of patients
achieving a blood pressure target of 130/80 mmHg [21].
In Sub-Saharan Africa, poor access to health care and
physician shortage are the major hindrances to the con-
trol of hypertension [13].
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In Uganda, control of hypertension among diabetic
patients is still suboptimal as only 56% of them have
their BP ≤ 140/80 mmHg [22].
A leading cause of suboptimal control of hypertension
in Uganda is the lack of screening among patients with
diabetes [22].
Other barriers to good blood pressure control are
limited resources, ill-equipped health facilities, scarce
medications, inadequate training of personnel, insuffi-
cient knowledge and experience of clinicians in the man-
agement of cardiovascular disease and hypertension, and
lack of guidelines [23].
Diabetes and hypertension share similar risk factors
such as insulin resistance, obesity, dyslipidemia, and
endothelial dysfunction [1]. Effective control of both
conditions requires a multifactorial approach. The
STENO 2 trial demonstrated the benefit of multiple
ASCVD risk factor management [24, 25].
Therefore, an intensive program that involves
counseling about medical nutrition therapy, physical
activity, smoking cessation, medication adherence, and
behavior change with ongoing support and frequent
follow-up are key for lifestyle management of weight,
dyslipidemia, hypertension, and glycemia in patients with
type 2 diabetes [25].
In the primary care setting, management of ASCVD
and hypertension is done by doctors, but these are few
[13] and spend less time with the patients; hence, there
is a need to shift this task to other health care cadres
such as nurses. There is evidence that nurses are
traditionally well versed in self-care support and play a
leading role in the administration of systematic educa-
tional interventions [26].
A systematic review of studies of nurse-led hyperten-
sion interventions in East Africa provided evidence that
nurse-led interventions are effective in screening, diag-
nosis, and treatment of hypertension [27].
In one integrative review on nurse-led care interven-
tions for high blood pressure control in Uganda, there
was strong evidence to support nurse-led care interven-
tions in the control of high blood pressure [28].
In Uganda, screening and management of ASCVD
and hypertension among diabetic patients is a
doctor’s role that takes place at health center IV,
district, and regional referral hospitals, yet it is the
nurses who spend most of the time with the patients
and are readily available.
Therefore, the scarce doctors who are also involved
in communicable disease care are stretched to
provide timely and comprehensive ASCVD risk and
hypertension screening and primary prevention in the
community. This leads to patients presenting late
with established cardiovascular disease for secondary
care that is very expensive and fatal.
Improvement in diabetes, hypertension, and ASCVD
care requires the transformation of the health system
rather than a reactionary approach. Therefore, Wagner’s
Chronic Care Model that improves care in health
systems at community, organization practice, and
patient levels will be adapted in this trial [29].
To our knowledge, no trial using the chronic care
model has been conducted to study the effects of a
nurse-led lifestyle choice and coaching intervention on
systolic blood pressure among patients with type 2 dia-
betes with high ASCVD risk in Uganda.
Objectives {7}
The aim of this study is to evaluate the effects of a
nurse-led lifestyle choice and coaching intervention on
systolic blood pressure and ASCVD risk factor profile
among patients with type 2 diabetes. We hypothesize
that a nurse-led lifestyle choice and coaching interven-
tion reduces systolic blood pressure and ASCVD risk
among type 2 diabetic patients with a high ASCVD risk.
Trial design {8}
This is a cluster-randomized study with a parallel design
in eight [8] diabetes clinics in the central region that
usually refer patients with cardiovascular complications
to Mengo Hospital as illustrated in Fig. 1. Consented pa-
tients with a high ASCVD risk score greater than 7.5%
will be eligible for the study. The health facilities include
Entebbe Grade B, Wakiso Health Centre IV, Kasangati
Health Center IV, Mityana Hospital, Kawolo Hospitals,
Mengo Hospital, Naguru Hospital, and Mpigi Health
Center IV. These will form fixed clusters for
randomization into intervention and control arms. Pa-
tients or the public were not involved in the study
design.
Methods: participants, interventions, and
outcomes
Study setting {9}
Out of the 10 health facilities in Central Uganda that
refer type 2 diabetic patients with cardiovascular disease
to Mengo Hospital, eight [8] clinics which referred most
patients in the preceding year were selected for the
study. The facilities have nurses, clinical officers, and
doctors who provide hypertension and ASCVD care
with no formal treatment protocols. They were selected
to allow for comparison between a nurse-led interven-
tion and a usual care, which is only possible in health
center IV and district hospitals. Eligible diabetic patients
will be recruited from Entebbe Grade B Hospital, Mengo
Hospital, Naguru Hospital, and Kasangati Health Center
IV, which are urban health facilities, and Wakiso Health
Center IV, Mpigi Health Center IV, Mityana Hospital,
and Kawolo Hospital, which are peri-urban health
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facilities. These facilities run a weekly diabetes clinic
where 50–120 patients are treated according to the size
of the health facility. Approximately 250–600 patients
with type 2 diabetes attend these clinics per week. The
facilities have well-organized manual patients’ registers.
Thus, intervention in these facilities will be handy in the
prevention and management of hypertension and ASCV
D among patients with type 2 diabetes.
Eligibility criteria {10}
The inclusion criteria for study health facilities are as
follows:
1. The study health facility must be running a regular
outpatient diabetes clinic.
2. Must be located in an urban or peri-urban area in
the central region.
3. The diabetes clinic must be having at least 85
outpatient visits per week to ensure the recruitment
of enough participants.
4. The minimum distance between health facilities
should be more than 6 km to minimize
contamination.
5. The health facilities should not share health
professionals to minimize intervention bias.
6. The diabetes clinic must be run by nurses and
clinical officers or medical officers with well-
maintained records and dispensary.
The eligibility criteria for study participants are as
follows:
Inclusion criteria:
1. Adult men and women with type 2 diabetes aged
40–79 years with a high ASCVD risk score of at
least 7.5% as calculated with the pooled cohort risk
equations
2. Willing to provide informed consent
Fig. 1 Study design. CVD, cardiovascular disease; ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol
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3. Asymptomatic for ASCVD (those without a history
of non-fatal myocardial infarction, stroke, heart fail-
ure, percutaneous coronary intervention, coronary
artery bypass surgery, or current atrial fibrillation)
Exclusion criteria:
1. Pregnant women (pooled cohort equation has not
been validated in pregnancy)
2. Those with other comorbidities such as chronic
kidney disease and liver disease
3. Patients who do not usually keep appointments,
that is, those who have attended clinics only once
per year
Who will take informed consent? {26a}
After confirming eligibility, trained study nurses will
obtain written informed consent from potential
participants.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Blood will be collected, but it will not be used for
genetic and molecular analysis in this trial and future.
Interventions
Explanation for the choice of comparators {6b}
Out of the 10 health facilities in Central Uganda that
refer type 2 diabetic patients with cardiovascular disease
to Mengo Hospital, eight [8] clinics which referred most
patients in the preceding year were selected for the
study. The facilities have nurses, clinical officers, and
doctors who provide hypertension and ASCVD care
with no formal treatment protocols. Health center IV
and above were selected to allow for comparison
between a nurse-led intervention and a usual care, which
is only possible in health center IVs and district
hospitals.
Intervention description{11a}
Nurse-led lifestyle change education and management at
the health facility
The purpose of this trial is to evaluate the effects of a
nurse-led lifestyle change education, management, and
coaching intervention on systolic blood pressure among
patients with type 2 diabetes with a high ASCVD risk
score of at least 7.5% as determined by the pooled co-
hort risk equations. The intervention will be targeted at
both cluster (group) and individual levels. The clusters
will be allocated in a 1:1 ratio between intervention and
usual care arms.
Our intervention is based on Wagner’s Chronic Care
Model (CCM) as shown in Fig. 2. Wagner’s Chronic Care
Model is the best-evidenced strategy to improve diabetes
outcomes in the primary care setting [29]. The CCM gives
a conceptual framework for reorganizing care from the
acute reactive system to a population-based proactively
planned care of patients with chronic illnesses such as dia-
betes, hypertension, and ASCVD [30].
Participants in the intervention group will be subjected
to the Nurse-led lifestyle change education, manage-
ment, and coaching intervention which comprised two
components. The first component is the facility-based
nurse-led lifestyle change education that is cluster-based,
protocol-led hypertension and ASCVD management and
treatment adherence counseling that is individualized.
The second component is the individualized home-
based coaching support.
Nurse-led lifestyle change education and management at
the health facility
Two nurses from each facility will be identified and
trained for 1 day at the study head office in Mengo
Hospital. The training will aim to enhance the capacity
of the nurses to screen and manage hypertension and
ASCVD. They will be trained on ASCVD risk factor
assessment with the pooled cohort risk equations,
initiation of treatment for hypertension and ASCVD,
when and where to refer, and principles of health
promotion and behavioral change.
At the end of the training, the nurses will be able to
provide group structured health education on ASCVD
prevention and management.
The health education sessions will last 30 min, and
they will be conducted every 2 months for 6 months.
The participants will be educated on the relationship
between ASCVD and diabetes, risk factor management,
and benefits of medication adherence. The education
sessions will be followed by a 15-min question and an-
swer session where participants will be allowed to ask
questions. The participants will be provided with an
ASCVD leaflet that will be published in both English
and the local language. The leaflet will be provided once
at the beginning of the trial, but they will be encouraged
by the study nurses to come with it every time they
come to the health education. The purpose of health
education is to produce an informed proactive patient.
Improvement in participants’ behavior will be shown
with treatment adherence rates and lifestyle change testi-
monies during sessions. During sessions, participants
will elect a leader (peer leader) who will be trained by
the study nurses to help in coordinating health educa-
tion sessions and referral of the critically ill from the
community to the health facility.
The nurses will provide protocol-based hypertension
and ASCVD management as shown in Fig. 3. The proto-
col has been developed by the principal investigator. The
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protocol will be used to guide the management and
provision of medicine (i.e., lipid-lowering agents, anti-
hypertensives). The protocol will give clear guidance on
how to determine patient stability and when to refer to a
clinical or medical officer in the respective facility or a
facility higher. This strategy underpins the task shifting
of hypertension and entire ASCVD management from a
clinical or medical officer to a well-trained and facili-
tated nurse with a well health-educated, informed, and
supported patient at the center. Therefore, improvement
in this capacity will be assessed by the number of pa-
tients on appropriate anti-hypertensives, lipid-lowering
agents, and referrals.
Coaching intervention
The second component of the intervention will be the
coaching support where individual participants in the
intervention group will be given support at home. The
study nurses will make individualized telephone calls,
send text messages, and operate a 24-h mobile telephone
service to answer study participants’ questions and con-
cerns. The phone calls will be structured along the
health education topics provided at the health facility. It
is anticipated that telephone calls will last for 7 min per
participant. Thus, for 194 participants, 22 h of calls will
be consumed each time the study participants are called.
Participants will be called 3 times during the entire trial
Fig. 2 The study conceptual framework. Adapted from Wagner’s Chronic Care Model [29]. HT, hypertension; ASCVD, atherosclerotic
cardiovascular disease
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period. The participant and the areas discussed will be
registered in the call log. Text messages will be sent
every after 2 months. The messages will contain topics
discussed during the health education talks and in the
leaflet. Every time messages are sent, they will be re-
corded in the text messages’ log.
The telephone calls and text messages will reinforce
individualized hypertension and ASCVD management
plan at home. The nurse-patient relationship which is
key in the chronic disease care model will be strength-
ened through calls and text messages. The intervention
components are as shown in Fig. 4.
The usual hypertension/ASCVD care
The control group of the study will comprise the usual
care that is the doctor- or clinical officer-led at health
centers IV and higher where either patients are referred
by nurses or refer themselves with symptoms of ASCV
D. In the usual care, patients with diabetes are not sub-
jected to ASCVD risk quantification. Nurses give general
health education on diabetes self-care practice which is
not structured along with primary hypertension and
ASCVD prevention and management. Health education
does not build a nurse-patient relationship with a well-
educated motivated patient at the center. All patients are
given the same management package irrespective of
their risk factor profile. Management of hypertension
and ASCVD in the health facilities in Uganda is not
protocol-based as every facility manages diabetes and
hypertension differently. Apart from the general Infor-
mation Education Communication materials at the
clinics, patients are not given information leaflets and
are not followed with phone calls and text messages and
neither can they call the health workers any time of the
Fig. 3 Protocol for ASCVD and hypertension management. ASCVD, atherosclerotic cardiovascular disease
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day. Patients are followed only in the clinics when they
are given review appointments by the doctors or clinical
officers. Nurses in these facilities have varied training
and skill in diabetes management.
Criteria for discontinuing or modifying allocated
interventions {11b}
Given the fact that the intervention components are
some of the routine procedures at the clinics, we
anticipate low risk. However, if a participant opts out, or
develops an adverse event, she or he will be
discontinued from the study.
Strategies to improve adherence to interventions {11c}
To reduce dropout rates, participants in the intervention
arm will be receiving a transport refund. The two
monthly calls that are part of the motivation component
will also be used to encourage participants to attend
follow-up visits. The follow-up log will be used to regis-
ter visits and also establish those defaulting and their
reasons for not attending.
Relevant concomitant care permitted or prohibited
during the trial {11d}
The participants in both intervention and control arms
will continue receiving hypertension, diabetes, and
ASCVD treatment as deemed appropriate by the health
workers in these facilities. The care in the intervention
arm will be provided by the trained study nurses
according to the study protocol. The care in the control
arm will be the usual management provided by the
medical officers, clinical officers, and nursing officers.
Provisions for post-trial care {30}
After the trial, all participants irrespective of their
randomization will continue with care in their facilities.
The results from the trial will be shared with all the
health facilities. Any finding that imparts on treatment
outcomes will be shared. Our trial is a low-risk study,
and we anticipate low rates of harm. However, in case of
an anticipated adverse event, standard operating proce-
dures will be followed.
Outcomes {12}
Primary outcomes
The primary outcome of the trial will be the mean
difference in the change in systolic blood pressure
between baseline and 6months between the intervention
and usual care groups at individual and cluster levels.
Secondary outcomes
The following are the secondary outcomes:
i) Absolute difference and relative change in the
predicted 10-year ASCVD risk between the inter-
vention and usual care groups at 6 months
Fig. 4 Intervention components. HT, hypertension; ASCVD, atherosclerotic cardiovascular disease; VHT, Village Health Team. 176 × 135 mm
(300 × 300 DPI)
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ii) Absolute changes in total cholesterol, low-density
lipoprotein cholesterol (LDL-C), glycated
hemoglobin, and body mass index at 6 months
iii) Differences between the groups in the change in the
proportion of patients reaching treatment goals for
systolic blood pressure, total cholesterol, LDL
cholesterol, glycated hemoglobin and body mass
index at 6 months
Participant timeline {13}
Participants will be enrolled and assessed following the
Standard Protocol Items: Recommendations for
Intervention Trials (SPIRIT) schedule as shown in Table 1.
Sample size {14}
To detect an 8.5-mmHg mean difference in systolic
pressure between the intervention and control arms, the
sample size was calculated basing on a study by Rudd
et al. [31]. The study evaluated the effects of a nurse-led
use of algorithm-based prescribing compared to usual
care where there was a mean change in systolic blood
pressure of 14.2 mmHg (standard deviation (SD) = 17.2)
in the intervention arm and 5.7 mmHg (SD = 18.7) in
the control arm [31].
To have an 80% power for the trial at a significance
level of 0.05, a 2-tailed test assuming an intracluster cor-
relation coefficient (ICC)of 0.035 for continuous clinical
outcomes for studies related to cardiovascular disease
and management in primary care practices [32] has been
used. Given that we shall have 4 fixed clinics (clusters)
per arm, the sample size for each arm has been calcu-
lated using the formula for a fixed number of equal-
sized clusters as described by Hemming et al. [33]. The
sample size for each arm will be 174. Assuming a 10%
loss to follow-up over the 6months, the final sample size
for each arm will be 193.3 rounded to 194 with each
cluster having 49 participants. We recognize that the
study may not be powered enough for the secondary
outcomes since the sample size has been calculated
based on the primary outcome.
Table 1 Enrollment and assessment schedule for the study (SPIRIT schedule)
Study period
Enrollment Allocation Post-allocation




Pooled coherent risk equation X
Allocation X
Intervention:
Nurse-led lifestyle choice and coaching
interventions
Assessments:




- Systolic blood pressure
- Total cholesterol
Proportion of patients at
target for:
- Glycated hemoglobin
- Systolic blood pressure
- Diastolic blood pressure
- Total cholesterol
- LDL cholesterol
Outcome variables 1) Mean change in systolic blood pressure
2) Absolute and relative change in predicted 10-year
ASCVD risk
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Recruitment {15}
The study nurses will carry out announcements during
clinic days to recruit patients into the study.
Patients’ files and the clinics’ registers will be reviewed
to identify eligible study participants. A list of these will
be generated from which they will be selected
consecutively.
The study nurses will provide potential study
participants with a copy of the informed consent in all
study clinics and approved protocol-specific education
material in the intervention clinics.
Assignment of interventions: allocation
Sequence generation {16a}
The unit of randomization will be the diabetes clinics
(clusters) attended by the participants whose ASCVD
score has been determined using the pooled cohort risk
equations. To ensure the balancing of the arms, the
clinics will be paired according to whether they are
urban or peri-urban. The urban clinics will comprise
Mengo Hospital, Naguru hospital, Entebbe Regional Re-
ferral Hospital, and Kasangati Health Center IV while
the peri-urban will include Mityana Hospital, Wakiso
Health Center IV, Kawolo Hospital, and Mpigi Health
Center IV. Two pairs of urban and peri-urban clinics
will be formed. These will be randomly allocated in a 1:1
ratio to intervention or control arms using a computer-
generated random sequence developed by a statistician
uninvolved in the study.
Concealment mechanism {16b}
An independent statistician will carry out the
randomization, and the sequence numbers will be kept
in sealed opaque envelopes away from the study clinics.
This will ensure the independence of the group
allocation from data collection and analysis procedures.
The participants who meet the eligibility criteria will be
consented. These will have their baseline assessments
(to) done. Allocation disclosure will occur after baseline
measurements in the presence of the study nurses and
the participants.
Implementation {16c}
The allocation and assignment to the intervention will
be at the level of the health facilities, and it will be done
by the independent statistician.
After confirming eligibility, trained study nurses will
obtain written informed consent and collect baseline
data that will be filled in the data collection forms.
Assignment of interventions: blinding
Who will be blinded {17a}
Due to the type of intervention, blinding of the
participants and study nurses will not be possible at data
collection, monitoring, and management. The
statistician conducting the data analysis will be blinded
till completion.
Procedure for unblinding if needed {17b}
Facility and group allocation will be revealed by the
principal investigator to the statistician after completion
of data analysis.
Data collection and management
Plans for assessment and collection of outcomes {18a}
After confirming eligibility, trained study nurses will
obtain written informed consent and collect data on
socio-demographic characteristics and treatment history
that will be filled in the data collection forms. Baseline
data on systolic blood pressure, total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein
cholesterol, glycated hemoglobin, body mass index, and
10-year predicted ASCVD risk score will be collected
and filled in the data collection forms.
Study nurses will measure the blood pressure using an
automated OMRON® digital blood pressure machine
with an appropriate cuff size placed on the upper arm
with the bladder of the cuff centered over the brachial
artery. An average of three blood pressure
measurements will be obtained.
Weight will be measured to the nearest 0.1 kg with the
subject standing motionless on the bathroom weighing
scale.
Height will be measured to the nearest 0.1 cm with the
subject standing in an erect position against a vertical
scale or portable stadiometer and with the head
positioned so that the top of the external auditory
meatus is in level with the inferior margin of the bony
orbit.
Body mass index (BMI) will be calculated as weight in
kilogram divided by squared height in meters.
Conventional BMI cutoffs will be used to classify the
study population into underweight (BMI < 18.5 kg/m2),
normal BMI (≥ 18.5 < 25 kg/m2, overweight BMI > 25 to
< 30 kg/m2), and obese > 30 kg/m2.
Waist and hip circumferences will be measured twice
to the nearest centimeter using a non-stretchable meas-
uring tape, and the mean values will be used for subse-
quent analysis.
Waist circumference (WC) will be measured halfway
between the lowest rib and the iliac crest with the
subject standing at the end of gentle inspiration. The hip
circumference (HC) will be measured at the level of the
greater trochanters. The waist to hip ratio (WHR) and
the waist to height ratio (WHtr) will be computed for
each participant.
After a 12-h fasting, standard calorimetric methods
will be used to assay fasting plasma glucose, total
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cholesterol, triglycerides(TG), and high-density lipopro-
tein cholesterol (HDL-C). Low-density lipoprotein chol-
esterol will be calculated using the Friedwald formula
when TG levels are equal or less than 4mmol/l. Low-
density lipoprotein cholesterol will be measured directly
when TGs are > 4 mmol/l.
Glycated hemoglobin (HbA1C) will be determined
by high-performance liquid chromatography (HPLC).
All HbA1c values will be converted to the Diabetes
Control and Complications Trial (DCCT) standard
levels: HbA1c (DCCT) = 0.923 × HbA1c (measured) +
1.345; R2 = 0.998 [34].
The predicted 10-year ASCVD risk will be calculated
by the pooled cohort risk equation [35].
Follow-up visits will be scheduled at 6 months after
the baseline visit. Anthropometric measurements, blood
pressure, predicted 10-year ASCVD risk, glycated
hemoglobin, total cholesterol, and BMI will be
measured.
Plans to promote participant retention and complete
follow-up {18b}
To reduce dropout rates, participants will be receiving a
transport refund. Periodical calls will be conducted to
ensure continual follow-up. A follow-up log will be used
to register visits and also establish those not attending
and the reasons for defaulting.
Data management {19}
The study nurses will be educated and trained by the
principal investigator on proper data correction and
completion of data correction forms in accordance with
the trial protocol.
At each health facility, data will be compiled into data
collection forms, which will be checked daily by the
study nurses for completeness. Data collection forms
will be secured in lockers at the health facilities and later
sent to the principal investigator quarterly for further
management. The principal investigator will send data
collection forms quarterly to the statistician. Data
collection forms will only bear study identification
numbers for confidentiality. Data will be entered into
the EPI-INFO program and then exported to SPSS stat-
istical program for analysis by the study statistician.
Confidentiality {27}
The principal investigator and study nurses will generate
codes for the study sites (health facilities). In each
facility, the participants will be given a participant
identification number in a register. From the health
facility codes and participant identification numbers, a
study identification number will be generated to be used
on the data collection forms and specimen containers to
protect their privacy.
The records will be kept in a locked location at the
study health facility only accessed by those working on
the study.
The participant’s name will not be used in any reports,
presentations, or publications resulting from this study.
The participant’s names will only be revealed in case of
referral for further treatment.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Blood will be collected, but it will not be used for
genetic or molecular analysis in this trial or future
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Participant characteristics will be described using simple
descriptive characteristics. We will use the mean and
standard deviation to describe normally distributed
continuous variables and the median and upper and
lower limits of the interquartile range to describe non-
normally distributed continuous variables. Normality of
continuous variables will be assessed by visual inspection
of histograms. Categorical data will be presented in
counts and percentages.
Data will be analyzed according to the intention-to-
treat (ITT) principle.
The primary outcome of the trial is the mean
difference in the change in systolic blood pressure
between baseline and 6months and between the
intervention and usual care groups at individual and
cluster levels. It will be expressed as the mean systolic
blood pressure difference between the groups (with 95%
CI).
This value will be measured as the difference between
matched diabetes clinics (intervention clinics minus
control clinics) in systolic blood pressure (systolic blood
pressure in the intervention period minus systolic blood
pressure in the baseline period). The hypothesis for this
study is that a nurse-led lifestyle choice and coaching
intervention reduces systolic blood pressure compared
to usual care among type 2 diabetic patients with high
ASCVD risk.
In this study, the same individuals will be assessed at
baseline and follow-up (cohort design), and analysis of
covariance (ANCOVA) will be used to analyze each indi-
vidual’s outcome at follow-up adjusted for that individ-
ual’s outcome at baseline with mixed-effects linear
regression or generalized estimating equations to assess
changes over time in systolic blood pressure as a con-
tinuous variable between clusters [36, 37]. A random
intercept representing each cluster will be added to each
model to account for the intra-cluster correlation (ICC).
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We shall adjust the analysis models by the balancing fac-
tor urban or peri-urban.
Appropriate analyses will be employed to assess the
secondary outcomes between study arms. Since sample
size calculation for the trial was based on the primary
outcome, the lack of significant differences between the
arms may be due to the true lack of differences or due
to inadequate power. Therefore, secondary outcome
interpretation will be cautiously done.
All analyses will be conducted using the SPSS software
version 25.
Interim analyses {21b}
No interim analyses are planned due to the low-risk na-
ture of the study.
Methods for additional analyses (e.g., subgroup analyses)
{20b}
No subgroup analyses will be performed.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
We anticipate missing data at random (MAR), where
missingness will not depend on the unobserved data but
conditional to the observed data. We shall use observed
data to impute missing values for patients with missing
data. Multiple imputations will be employed to take
uncertainty into account by replacing each missing value
with a set of possible values to create multiple imputed
values. The number of imputations will be determined
by the percentage drop out rate. In this study, we
anticipate a 10% drop out; therefore, we are planning 10
imputations. We shall perform sensitivity analysis that
will weaken the missing data assumption to assess
departures in the primary analysis.
Plans to give access to the full protocol, participant-level
data, and statistical code {31c}
Access to the full protocol, participant-level data, and
statistical code will only be possible through
authorization by the principal investigator.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
The study coordinating center is at Mengo Hospital.
The coordinating center comprised the principal
investigator, study coordinator, and data entry assistant.
The principal investigator and the study coordinator
have created the study trial manual and have established
the data collection processes including the standard
operating procedures. The principal investigator working
in conjunction with the other authors (DK, RW and SB)
was charged with the conception of the research
question and developed the proposal which was
submitted for approval. The principal investigator and
study coordinator trained study nurses and provide
routine communication to the study health facilities.
The study coordinator is in charge of routine
communication with the study facilities. The study
coordinator prepares the monthly progress report to the
Mengo Hospital Ethics Committee. The principal
investigator, study coordinator, and data entry assistant
are responsible for the data oversight. The study
coordinator is in charge of logistical provision to the
study facilities. The PI and study coordinator work in
conjunction with the study nurses to monitor and report
adverse events. An independent trial steering committee
to oversee the trial has been formed. The Trial Steering
Committee comprised an independent epidemiologist,
diabetologist, cardiologist, biostatistician, principal
investigator, and study coordinator. The independent
trial steering committee oversees the trial. Study nurses
identify and recruit potential participants and guide
them through the consenting process. The Trial Steering
Committee (TSC) meets every after 2 months during the
trial. The trial does not have stake holder and public
involvement group (SPIG).
Composition of the data monitoring committee, its role,
and reporting structure {21a}
The data will be monitored by the team from the
coordinating center.
Adverse event reporting and harms {22}
The study is largely a low-risk one. However, in case of
any adverse event or harm, the study participants will be
required to inform the study nurse immediately. If the
patient develops an AE, he or she will be discontinued
from the study. The study nurse will record the event
and will follow the study standard operating procedures
on the management of adverse events and harms. The
serious adverse event will be reported to the coordinat-
ing center in Mengo Hospital.
Frequency and plans for auditing trial conduct {23}
We have no plans for independent trial auditing.
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
Any protocol amendments that may affect the study
design or conduct and patient safety will be submitted
to the Mengo Hospital Research Ethics Committee for
approval. If approved, this will be communicated to the
Uganda National Council of Science and Technology
and the study health facilities. The Pan African Trial
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Registry and the journal publishing the protocol will be
appropriately informed.
Dissemination plans {31a}
We will disseminate the findings from this trial through
peer-reviewed publications and local and international
scientific meetings. A project report written in non-
technical language will be sent to all participants.
Discussion
Atherosclerotic cardiovascular disease (ASCVD) is a
leading cause of morbidity and mortality among patients
with type 2 diabetes in Uganda. Hypertension which is a
major contributor to ASCVD is highly prevalent,
undiagnosed, and poorly controlled. One of the reasons
for poor control of hypertension and ASCVD in the
primary care setting is the scarcity of doctors [13].
Nurses are readily available and spend more time with
the patients and are traditionally well versed in self-care
and administration of systematic educational interven-
tions [27]. Thus, there is a need to shift the task of man-
agement of hypertension and ASCVD from doctors to
nurses. However, there is a paucity of data on nurse-led
hypertension management among patients with type 2
diabetes in our setting. To the best of our knowledge,
this is the first trial in Uganda that examines the effect
of a nurse-led lifestyle choice and coaching intervention
on systolic blood pressure among patients with type 2
diabetes with a high ASCVD risk. The intervention is
based on Wagner’s chronic care model that has been ex-
tensively studied in diabetes care. We believe findings
from this trial will be useful in drafting national guide-
lines on the management of hypertension and ASCVD
among patients with type 2 diabetes.
Trial status
Protocol version 03, 2021 January 19
Recruitment is planned to start on 28 December 2020
and is expected to last for 6 months until 1 July 2021.
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